Abstract | OBJECTIVE: METHODS: RESULTS: After 3 months of U-500 insulin use, hemoglobin A1c dropped significantly from a mean baseline of 8.3% to a mean value of 7.3% (P = .003), and this improvement was sustained for over 66 months of use. There was no significant overall change in body weight or total daily insulin dose over time with the use of U-500 insulin. For those subjects who did gain weight, there was a parallel increase in insulin dose that correlated with weight gain. The overall incidence of severe hypoglycemia was low over the study period, with a mean occurrence of 0.1 episodes per patient per year. CONCLUSIONS:
|
Authors | Wendy S Lane, Stephen L Weinrib, Jonathan M Rappaport, Christopher B Hale, Lynley K Farmer, Rebecca S Lane |
Journal | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
(Endocr Pract)
2013 Mar-Apr
Vol. 19
Issue 2
Pg. 196-201
ISSN: 1934-2403 [Electronic] United States |
PMID | 23186973
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Body Mass Index
- Cohort Studies
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy, mortality)
- Female
- Follow-Up Studies
- Humans
- Hyperglycemia
(prevention & control)
- Hypoglycemia
(epidemiology, prevention & control)
- Incidence
- Insulin Infusion Systems
- Insulin Resistance
- Insulin, Regular, Human
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- North Carolina
(epidemiology)
- Obesity
(complications)
- Obesity, Morbid
(complications)
- Off-Label Use
- Osmolar Concentration
- Retrospective Studies
- Weight Gain
(drug effects)
|